Table 1

Summary estimates for intraocular pressure at 3 months derived from the pairwise meta-analysis

Control	Experimental	Total no of studies	Mean difference*	95%CI		τ²†	I²‡
Control	Experimental	Total no of studies	Mean difference*	Low	Up	τ²†	I²‡
Placebo	Bimatoprost 0.01%	1	−4.60	−5.60	−3.60	NA	NA
	Latanoprost	1	−3.10	−3.98	−2.22	NA	NA
	Unoprostone	1	−0.30	−1.50	0.90	NA	NA
	Betaxolol	2	−3.16	−4.17	−2.15	0.3	52%
	Brimonidine	1	−2.30	−3.99	−0.61	NA	NA
	Brinzolamide	1	−2.22	−3.48	−0.96	NA	NA
	Dorzolamide	4	−2.48	−3.84	−1.12	1.3	76%
	Levobunolol	2	−7.90	−8.94	−6.85	0.0	0%
	Timolol	4	−3.75	−4.75	−2.76	0.6	58%
Bimatoprost 0.01%	Latanoprost	2	1.02	0.68	1.37	0.0	0%
	Tafluprost	1	2.30	−0.91	5.51	NA	NA
	Travoprost	2	1.50	−1.98	4.97	5.2	80%
Bimatoprost 0.03%	Latanoprost	7	0.99	0.46	1.53	0.3	61%
Bimatoprost 0.03%	Travoprost	8	0.44	−0.52	1.40	1.4	86%
Latanoprost	Latanoprostene bunod	1	−1.23	−1.76	−0.70	NA	NA
	Tafluprost	3	−0.99	−1.92	−0.07	0.0	0%
	Unoprostone	6	2.90	2.16	3.63	0.3	37%
	Travoprost	7	−0.15	−1.30	1.00	1.9	87%
Apraclonidine	Timolol	2	−0.44	−3.91	3.03	5.6	89%
Betaxolol	Latanoprost	2	−1.84	−3.22	−0.47	0.0	0%
	Unoprostone	1	0.60	0.09	1.11	NA	NA
	Dorzolamide	2	−0.21	−0.82	0.40	0.0	0%
	Levobunolol	2	−4.65	−10.13	0.84	13.3	84%
	Timolol	6	−1.30	−2.46	−0.13	1.2	67%
Brimonidine	Latanoprost	5	−1.22	−2.13	−0.31	0.8	78%
	Betaxolol	1	2.00	0.90	3.10	NA	NA
	Brinzolamide	2	0.90	0.39	1.42	0.0	0%
	Timolol	4	0.42	0.04	0.81	0.0	0%
	Travoprost	1	−1.20	−3.77	1.37	NA	NA
Brinzolamide	Dorzolamide	2	−0.34	−0.84	0.16	0.0	0%
Carteolol	Levobunolol	1	−2.90	−4.59	−1.21	NA	NA
	Timolol	4	−0.27	−1.11	0.57	0.4	60%
Dorzolamide	Latanoprost	1	−2.90	−3.70	−2.10	0.0	NA
Levobunolol	Timolol	9	0.11	−0.40	0.62	0.1	15%
Timolol	Bimatoprost 0.03%	6	−2.06	−2.36	−1.75	0.0	0%
	Latanoprost	15	−1.18	−1.65	−0.70	0.6	76%
	Latanoprostene bunod	2	−1.42	−1.84	−1.01	0.0	0%
	Tafluprost	2	−0.50	−1.12	0.12	0.1	38%
	Unoprostone	2	0.94	−0.43	2.31	0.9	87%
	Brinzolamide	3	1.10	0.52	1.69	0.0	0%
	Dorzolamide	4	0.99	0.34	1.64	0.1	26%
	Travoprost	4	−0.89	−1.26	−0.52	0.0	0%
Travoprost	Tafluprost	1	−1.30	−2.93	0.33	NA	NA
Total	16 drugs	138§

, PGA
*Difference between the reduction in IOP during the study of the experimental drug and the control drug (mean difference under 0 favours the experimental drug). Results presented in bold are significant.
†τ² describes the underlying between-study variability.
‡I² is the percentage of variability in the treatment estimates which is attributable to heterogeneity.
§106 trials considered: 93 two-arm trials, 11 three-arm trials and 2 four-arm trials.
IOP, intraocular pressure; NA, not available; PGA, prostaglandin analogue.